Navigation Links
Biodegradable stent proves non-inferior to drug-eluting stent
Date:5/21/2013

21 May 2013, Paris, France: The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine months in the results of an imaging substudy reported at EuroPCR 2013 today.

The BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to quantitatively assess neointimal hyperplasia and stent apposition at nine months after treating patients with symptomatic coronary artery disease due to de novo stenotic lesions. Patients were randomly assigned to receive either the Orsiro (Biotronik) or the Xience Prime stent (Abbott Vascular). Images from baseline and the nine-month follow-up were analysed by independent and blinded core laboratories.

Results showed no difference in the angiographic endpoint of in-stent late lumen loss between the two stents at nine months (0.10+0.32mm with the Orsiro stent vs. 0.11 + 0.29mm with the Xience Prime stent, p non-inferiority=<0.0001). Rates of target lesion failure were also similar at nine months (4.8% vs. 5.3%, p=0.47).

The IVUS substudy showed somewhat less neointimal hyperplasia over nine months with the Orsiro stent (0.16) than the Xience stent (0.43, p=0.043) with 100% stent apposition. 
Similarly, neointimal area as assessed by OCT at nine months was somewhat less with the Orsiro stent (0.74+0.38mm2 ) than with the Xience stent (1.00+0.44mm2, p=0.024). The proportion of well-apposed struts was similar with the two stents and the proportion of covered struts was slightly higher with the Orsiro stent (98.3% vs. 97.5%, p=0.042).

Reporting the results, Stephan Windecker, Professor and Chief of Cardiology, Swiss Cardiovascular Center and Clinical Trials Unit Bern, Bern University Hospital, Switzerland, said, "The Orsiro sirolimus-eluting stent with a biodegradable polymer was
'/>"/>

Contact: Isabelle Uzielli
iuzielli@europcr.com
33-612-233-492
European Society of Cardiology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Experiencing existential dread? Tylenol may do the trick
2. Scientists identify gene that is consistently altered in obese individuals
3. Metal stents are effective treatment for blocked bile ducts
4. Brain stent offers alternative to shunt for fixing potentially blinding vein narrowing
5. Scores that evaluate newborn intensive care units are inconsistent
6. Students in Educational First Steps Assisted Centers Show Persistent Benefits Far Beyond Early Childhood According to University of Texas at Dallas Study
7. Personal epigenetic signatures found consistent in prostate cancer patients metastases
8. Patient expectations of acute bronchitis not consistent with the best evidence
9. RSNA: New Study Finds Brain Angioplasty and Stents Safe and Effective for Stroke Patients
10. Study Supports Use of Brain Stents for Certain Stroke Patients
11. Brain angioplasty and stents found safe and effective for stroke patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the world ... be spotlighting its award-winning print and artwork inspection solutions, ScanProof and ArtProof ... 17 at the Olympia London, booth #F33 , Be the first to get a ...
(Date:9/3/2015)... ... , ... Hunters Creek Retrievers is again honored to salute America's ... Puppy. Celebrate Fall 2015 with unlimited Free Hugs and K9 Kisses from a premiere ... Christmas with an extra big smile. , This adorable trained Lab Pup is ...
(Date:9/3/2015)... ... September 03, 2015 , ... A scar is an unavoidable result of incision or ... of the body's ability to heal itself. The appearance of a scar is dependent on ... age, genes, and skin pigmentation. ”Many scars fade to near invisibility on their own over ...
(Date:9/3/2015)... MS (PRWEB) , ... September 03, 2015 , ... ... that their team will be participating at the highly anticipated Mississippi Gulf Babypalooza ... expectant mothers coming from all over, from Gulfport, Biloxi, and beyond. We will ...
(Date:9/3/2015)... Rosa, CA (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases of ... One in seven men will be diagnosed with prostate cancer during their lifetime. While only ... to six of every 10 men by age 65, according to the American Cancer ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3
... increase in adult obesity rates in 31 states during the past ... fatal diseases such as// diabetes, stroke and cancer. ... efforts to curb the overweight epidemic, according to a new report ... titled F as in Fat: How Obesity Policies Are Failing America, ...
... Last year about 22,000 operations were cancelled by 34 hospitals ... to the report from these hospitals thousands of patients had ... be admitted to for elective surgery in 2005 had no ... in Dublin had to cancel 4,281 operations last year. Of ...
... shows that California is the fifth worst in the nation ... ,Texas was the worst with an uninsured ... was uninsured. Minnesota had the best record with only 8.7 ... ,New Mexico was noted to have an uninsured rate of ...
... healthcare problem, which has tickled the curiosity of researchers. To ... numbers of myths doing the rounds. To dispel the myths, ... from time to time. , ,A government ... obesity rates by 2010, where one in five girls between ...
... Papworth Hospital, Cambridge, in 1980 for cardiomyopathy died on Sunday ... heart transplant patient having survived for 26 years after undergoing ... diagnosed with cardiomyopathy and had a heart transplant last year. ... muscle becomes inflamed and does not work properly. ...
... specialists declared yesterday that coughing costs the UK economy ... of productivity when sufferers are not well costs approximately ... , ,According to the British Thoracic Society (BTS), ... asthma, drugs or environment factors. ,The BTS ...
Cached Medicine News:Health News:Rise in Obesity Rates in 31 States 2Health News:Rise in Obesity Rates in 31 States 3Health News:Cancellations of Operations touch 22,000 2
(Date:9/2/2015)... Sept. 2, 2015  Research and Markets ( ... "An Introduction to the Medical Devices Directive ... to their offering. This seminar ... device legislation. It will explain the Directives and ... Bodies, how to choose one and outline what ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. Advances in understanding ... opened new avenues and possibilities for improved drug ... systems, enzymes, and receptors that control the penetration ...
(Date:9/2/2015)... 2015  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, announced today that the first ... 1/2a clinical trial of AGT-181 in patients with ... AGT-181 is an investigational enzyme replacement therapy ... most severe form of MPS I, Hurler syndrome, ...
Breaking Medicine Technology:Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... -- MAP,Pharmaceuticals, Inc. today announced that it will ... clinical program at the 49th,Annual American Headache Society ... The poster presentation, which was,accepted as a late-breaker, ... of Inhaled Dihydroergotamine Mesylate,via a Novel Inhaler (Tempo(TM) ...
... Professor Home said: , "The editorials published by ... disregarded important pieces of data that,are extremely relevant ... data that showed no evidence,of any increase in ... Philip Home , CONTACT: Professor Philip Home, (44) ...
Cached Medicine Technology:MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: